ClinicalTrials.gg
CompletedNCT03934099Updated Dec 3, 2025Results posted

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

A Phase 2 interventional study of LC350189 formulated capsule and Placebo in Gout and Hyperuricemia, sponsored by LG Chem. Completed at 34 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by LG Chem · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.

Enrollment
3rd of 11
156 · median 37
Started
2019
with 2 others
Phase 2
Only one
of the 11
Registered
3rd of 11
by date

Among the 11 studies in Gout by LG Chem, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is the only one in phase 2, and was the 3rd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by LG Chem as a file.
02

Study summary

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects or the subject's legally acceptable representatives who sign a written form prior to the initiation of any study procedures.
  2. Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology (ACR) criteria.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant).
  2. Subjects experiencing an active acute gout attack within 3 weeks prior to screening (Visit 1).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    LC350189 50mg

    LC350189 50mg, Once a day (QD)

    Drug: LC350189 formulated capsule

  • Experimental
    LC350189 100mg

    LC350189 100mg, QD

    Drug: LC350189 formulated capsule

  • Experimental
    LC350189 200mg

    LC350189 200mg, QD

    Drug: LC350189 formulated capsule

  • Placebo comparator
    Placebo

    Placebo, QD

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84

    sUA level was measured at Day 84

    Time frame: Day 84

Secondary outcomes

  1. Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84

    sUA level was measured at Day 84

    Time frame: Day 84

  2. Maximum Percent Reduction in sUA (Serum Uric Acid) Level

    sUA level was measured at Day 1, 14, 28, 56, and 84

    Time frame: Up to Day 84

07

Results

Posted Dec 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneLC350189 50mgLC350189 100mgLC350189 200mgPlacebo
Started34383734
Completed30323432
Not completed4632
Withdrew: Adverse event0310
Withdrew: Lost to follow-up1211
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject2011
Withdrew: Other reasons0100

Outcome measures

PrimaryPercentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84

sUA level was measured at Day 84

Time frame:
Day 84
Reported as:
Number · Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84
Percentage of participantsLC350189 50mgLC350189 100mgLC350189 200mgPlacebo
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 8447.144.762.22.9
SecondaryPercentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84

sUA level was measured at Day 84

Time frame:
Day 84
Reported as:
Number · Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84
Percentage of participantsLC350189 50mgLC350189 100mgLC350189 200mgPlacebo
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 8458.863.278.42.9
SecondaryMaximum Percent Reduction in sUA (Serum Uric Acid) Level

sUA level was measured at Day 1, 14, 28, 56, and 84

Time frame:
Up to Day 84
Reported as:
Mean · Percentage of reduction in sUA
Maximum Percent Reduction in sUA (Serum Uric Acid) Level
Percentage of reduction in sUALC350189 50mgLC350189 100mgLC350189 200mgPlacebo
Maximum Percent Reduction in sUA (Serum Uric Acid) Level-46.67 ± 13.560-50.64 ± 19.127-66.79 ± 15.787-11.20 ± 8.814

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LC350189 50mg0/34 (0%)0/34 (0%)15/34 (44.1%)
LC350189 100mg0/38 (0%)0/38 (0%)13/38 (34.2%)
LC350189 200mg0/37 (0%)0/37 (0%)21/37 (56.8%)
Placebo0/34 (0%)0/34 (0%)8/34 (23.5%)
Most frequent other events
Most frequent other events
EventLC350189 50mgLC350189 100mgLC350189 200mgPlacebo
Gout flareMetabolism and nutrition disorders9/346/3810/376/34
Blood creatine phosphokinase increasedInvestigations1/342/386/371/34
Coronavirus test positiveInvestigations2/340/380/370/34
Back painMusculoskeletal and connective tissue disorders2/340/380/370/34
Blood pressure increasedInvestigations0/341/382/370/34
Transaminases increasedInvestigations0/340/382/370/34
DiarrehoeaGastrointestinal disorders1/342/381/371/34
HeadacheNervous system disorders0/342/380/370/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)LC350189 50mgLC350189 100mgLC350189 200mgPlaceboTotal
Mean52.0 ± 9.6056.6 ± 10.6454.6 ± 10.6655.4 ± 9.9754.7 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)LC350189 50mgLC350189 100mgLC350189 200mgPlaceboTotal
Female11259
Male33373529134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LC350189 50mgLC350189 100mgLC350189 200mgPlaceboTotal
Hispanic or Latino6107730
Not Hispanic or Latino28283027113
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LC350189 50mgLC350189 100mgLC350189 200mgPlaceboTotal
American Indian or Alaska Native01001
Asian12205
Native Hawaiian or Other Pacific Islander01203
Black or African American366520
White30272529111
More than one race01203
Unknown or Not Reported00000
08

Study locations

34 sites
  • Synexus Clinical Research
    Birmingham, Alabama 35211, United States
  • Synexus Clinical Research
    Chandler, Arizona 85224, United States
  • Synexus Clinical Research
    Mesa, Arizona 85206, United States
  • Synexus Clinical Research
    Tucson, Arizona 85712, United States
  • Preferred Research Partner
    Little Rock, Arkansas 72211, United States
  • Health Awareness Inc
    Jupiter, Florida 33458, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Miami Dade Medical Research Institute
    Miami, Florida 33176, United States
  • Meridien Research
    St. Petersburg, Florida 33709, United States
  • Clinical Research Trials of Florida, Inc
    Tampa, Florida 33607, United States
  • Avita Clinical Trials
    Tampa, Florida 33613, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • Synexus Clinical Research
    Chicago, Illinois 60602, United States
  • Synexus Clinical Research
    Richfield, Minnesota 55423, United States
  • Olive Branch Family Medical Cente
    Olive Branch, Mississippi 38654, United States
  • Synexus Clinical Research
    St Louis, Missouri 63141, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Synexus Clinical Research
    Omaha, Nebraska 68144, United States
  • Synexus Clinical Research
    Henderson, Nevada 89052, United States
  • OnSite Clinical Solutions
    Charlotte, North Carolina 28226, United States
  • OnSite Clinical Solutions
    Charlotte, North Carolina 28277, United States
  • Synexus Clinical Research
    Akron, Ohio 44311, United States
  • Synexus Clinical Research
    Cincinnati, Ohio 45236, United States
  • Synexus Clinical Research
    Columbus, Ohio 43212, United States
  • Paramount Medical Research and Consulting
    Middleburg Heights, Ohio 44130, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Synexus Clinical Research
    Anderson, South Carolina 29621, United States
  • Avant Research Associates
    Austin, Texas 78704, United States
  • Synexus Clinical Research
    Dallas, Texas 75234, United States
  • Discovery MM Services Incorporated
    Houston, Texas 77450, United States
  • Synexus Clinical Research
    San Antonio, Texas 78229, United States
  • Synexus Clinical Research
    Salt Lake City, Utah 84123, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in May 2021, 17 months.

Results were first posted in Dec 2025, 4 years 7 months after primary completion. A results delay was requested in Jan 2022.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 17 months is above that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2019
First posted
May 1, 2019
StartActual
Dec 2, 2019
Primary completionActual
May 3, 2021
CompletionActual
May 17, 2021
Results delay requested
Jan 10, 2022
Results first posted
Dec 3, 2025
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03934099
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
May 1, 2019
Start date
Dec 2, 2019
Primary completion
May 3, 2021
Completion
May 17, 2021
Results posted
Dec 3, 2025
Last update
Dec 3, 2025

Study contacts

Hyungjin Cho, MD
study director · LG Chem, Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigulixostat

Start the discussion